HSF1 and cancer: Interestingly, HSF1 was overexpressed, and paclitaxel treatment did not degrade HSF1 protein in drug-resistant cancer cells unlike in parent cells; this phenomenon was more dominant in paclitaxel-resistant cells, such as A549-taxolR cells, than in doxorubicin-resistant cells, such as T47D-doxR cells.